Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
Identifieur interne : 001E59 ( Main/Exploration ); précédent : 001E58; suivant : 001E60Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
Auteurs : Andy Kilianski [États-Unis] ; Susan C. Baker [États-Unis]Source :
- Antiviral research [ 0166-3542 ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000030
- to stream PascalFrancis, to step Curation: 000064
- to stream PascalFrancis, to step Checkpoint: 000027
- to stream Main, to step Merge: 001E74
- to stream Main, to step Curation: 001E59
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0035776</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0035776 INIST</idno><idno type="RBID">Pascal:14-0035776</idno><idno type="wicri:Area/PascalFrancis/Corpus">000030</idno><idno type="wicri:Area/PascalFrancis/Curation">000064</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000027</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000027</idno><idno type="wicri:doubleKey">0166-3542:2014:Kilianski A:cell:based:antiviral</idno><idno type="wicri:Area/Main/Merge">001E74</idno><idno type="wicri:Area/Main/Curation">001E59</idno><idno type="wicri:Area/Main/Exploration">001E59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1><s2>Maywood, IL 60153</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Cell</term><term>Entry inhibitor</term><term>In vitro</term><term>Medical screening</term><term>Middle East respiratory syndrome</term><term>RNA-directed RNA polymerase</term><term>Screening</term><term>Severe acute respiratory syndrome virus</term><term>Spectrum</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>In vitro</term><term>Cellule</term><term>Antiviral</term><term>Criblage</term><term>Dépistage</term><term>Virus syndrome respiratoire aigu sévère</term><term>Spectre</term><term>RNA-directed RNA polymerase</term><term>Inhibiteur d'entrée</term><term>Syndrome respiratoire du Moyen-Orient</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name></region><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0035776
|texte= Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
}}
| This area was generated with Dilib version V0.6.33. |  |